For many physicians, the U.S. Supreme Court has traditionally felt distant — relevant perhaps to national policy debates, but rarely to day-to-day clinical work. That distance is rapidly shrinking. “Now is, I think, a pretty revealing time to talk about how the Supreme Court affects all of us, not just in our personal views, not just in our political views, but actually in our professional lives,” said legal scholar and Georgetown Law professor Stephen Vladeck, JD,  during Monday’s Keynote Series presentation at the ATS 2026 International Conference.

Recently, a series of structural and doctrinal shifts has fundamentally changed how Supreme Court decisions influence health care delivery, regulation, and patient care. “The Supreme Court’s behavior over the last five years has really dramatically broadened the aperture through which the Supreme Court matters to you,” Mr. Vladeck said.

For clinicians, this means that regulations governing medications, devices, insurance coverage, and public health interventions are increasingly shaped — or disrupted — by litigation, Mr. Vladeck said. Federal agencies such as the FDA, CMS, HHS, and EPA have long set the framework for medical regulation, but that framework is now more vulnerable than ever to judicial reinterpretation.

One of the most consequential changes is the Supreme Court’s abandonment of Chevron deference, a doctrine that for decades required courts to defer to reasonable agency interpretations of ambiguous statutes. “In 2024, a case called Loper Bright, the Supreme Court got rid of Chevron rather unceremoniously and said, ‘No, no, no. Chevron is anti-Democratic because it gives too much power to unelected agency bureaucrats,’” he said.

The practical implication is profound. Instead of relying on agency expertise that is grounded in scientific and clinical data, judges now have greater authority to assert their own interpretations. For physicians, this disrupts regulatory stability, particularly in processes like drug approvals, labeling requirements, and safety standards.

Compounding this shift is a change in how courts handle statutes of limitations for challenging regulations. Previously, rules had to be contested within six years of their issuance. “Now, SCOTUS has said that it’s six years from when the plaintiff is harmed, even if the regulation is 30, 40, 50 years old,” Mr. Vladeck said. “What that means is, a corporation can create a new subsidiary that didn’t exist until now, and all of a sudden, that subsidiary is harmed by the regulation and that starts the clock over.”

This opens the door for decades-old health care regulations to be revisited and potentially overturned, creating instability in long-standing clinical and administrative practices.

The Supreme Court has also increased its scrutiny of how agencies implement rules. Even minor procedural missteps — such as how public comments are processed — can now invalidate major policies. This creates new opportunities for litigants to challenge regulations, often leading to nationwide consequences. At the same time, litigants can strategically file cases in jurisdictions with favorable judges. Certain courts allow plaintiffs to effectively “shop” for judges more likely to rule in their favor, accelerating legal challenges and increasing variability in outcomes across the country.

Another critical development is the Supreme Court’s growing use of emergency orders — often referred to as the “shadow docket.” These allow the Court to intervene early in litigation, sometimes issuing nationwide rulings before cases are fully adjudicated.

This creates rapid policy shifts. A federal district court may block a regulation one day, an appellate court may reverse it the next, and the Supreme Court may intervene shortly thereafter — all before a final ruling is reached. The resulting volatility directly affects clinical practice, particularly in areas like reproductive health, medication access, and public health policy.

Mr. Vladeck underscored the uncertainty this creates: “How do we know why the Supreme Court intervened? Short answer: we don’t.”

For clinicians, the key takeaway is increasing instability in the regulatory environment. Rules governing insurance coverage, prescription practices, and treatment protocols may change quickly and unpredictably.

This has several practical implications: Clinical guidelines may require more flexibility, incorporating contingency planning for legal changes; drug availability and prescribing pathways may be disrupted, as seen in litigation over medications like mifepristone; and administrative compliance becomes more complex, with shifting interpretations of federal rules.

Amidst this evolving landscape, Mr. Vladeck recommended that health care professionals become more engaged with legal developments affecting their field. He clarified this does not mean one needs to become an expert, but rather recognize that judicial decisions now play a direct role in shaping clinical practice. He offered his newsletter on Substack as one way of staying informed.

Scenario planning — considering how sudden regulatory changes might affect operations — is increasingly important, he said. Collaboration with legal counsel and institutional leadership can help health care organizations respond more effectively to rapid shifts.

Mr. Vladeck made clear that the Supreme Court is no longer a distant institution for health care professionals. Its decisions now shape the regulatory environment with increasing speed and unpredictability. As a result, physicians must be prepared for a landscape in which legal developments can directly influence patient care, often with little warning.